Last checked at 26 Oct 2018 07:00
BEXIMCO PHARMACEUTICALS LTD.
26 October 2018
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Ltd. ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 25 October 2018. Please see further detail as follows:
1. | To recommend the approval of the Financial Statements for the year ended 30 June 2018 | : | The Audited Financial Statements for the year ended 30 June 2018 have been approved. The full accounts are expected to be announced by 7 November 2018 |
2. | Date & Time of 42nd AGM of the Company for the year ended 30 June 2018 | : | 22 December 2018 at 10.30 am |
3. | Venue of AGM | : | Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh |
4. | Proposed Dividend for the year ended 30 June 2018 | : | 12.5% Cash Dividend (i.e. Tk 1.25 per share) |
5. | Record date | : | 26 November 2018 |
During the meeting, the Board of Directors also decided to hold an Extraordinary General Meeting (EGM) to pass Special Resolutions to amend certain Clauses of Memorandum of Association and Articles of Association of the Company. The following decisions were made with respect to the EGM:
Record date | 26 November 2018. |
Date & Time of EGM | 22 December 2018 at 10.00 am Bangladesh Standard Time |
Venue | Beximco Industrial Park, Sarabo, Kashimpur, Gazipur |
Comparative Financial Disclosures:
Beximco Pharmaceuticals Limited (Stand-alone)
Particulars | Year ended 30 June 2018 | Year ended 30 June 2017 |
Net Profit after Tax | Tk.2,558,971,263 | Tk.2,226,695,124 |
Earnings Per Share (EPS) | Tk.6.31 | Tk.5.49 |
Net Asset Value (NAV) | Tk.27,104,389,931 | Tk.25,072,425,900 |
Net Asset Value per share (NAVPS) | Tk.66.83 | Tk.61.82 |
Net Operating Cash Flow Per Share (NOCFPS) | Tk.4.56 | Tk.5.89* |
* Restated
Beximco Pharmaceuticals Limited and its Subsidiary (Consolidated)
Particulars | Year ended 30 June 2018 |
Net Profit after Tax | Tk.2,532,654,301 |
Earnings Per Share (EPS) | Tk.6.25 |
Net Asset Value (NAV) | Tk.27,081,962,616 |
Net Asset Value per share (NAVPS) | Tk.66.78 |
Net Operating Cash Flow Per Share (NOCFPS) | Tk.4.49 |
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel: +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Tom Price
Tel: +44 (0)20 3861 6625
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 4,200 employees of the Company.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.